Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.720
+0.090 (1.94%)
At close: Sep 26, 2025, 4:00 PM EDT
4.720
0.00 (0.00%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Recursion Pharmaceuticals stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $7.25 forecasts a 53.60% increase in the stock price over the next year.
Price Target: $7.25 (+53.60%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +69.49% | Sep 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +69.49% | Jul 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $5 | Hold | Initiates | $5 | +5.93% | Jul 3, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $5 | Hold | Maintains | $8 → $5 | +5.93% | Jun 16, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +69.49% | May 6, 2025 |
Financial Forecast
Revenue This Year
73.02M
from 58.84M
Increased by 24.09%
Revenue Next Year
88.35M
from 73.02M
Increased by 20.99%
EPS This Year
-1.64
from -1.69
EPS Next Year
-1.28
from -1.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 100.3M | 162.8M | |
| Avg | 73.0M | 88.3M | |
| Low | 47.4M | 58.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 70.4% | 122.9% | |
| Avg | 24.1% | 21.0% | |
| Low | -19.5% | -19.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.35 | -0.85 | |
| Avg | -1.64 | -1.28 | |
| Low | -1.76 | -1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.